Full video transcriptClick to expand
Auto-generated transcript of @dr..alex.tatem's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:00Dihexa, aka the limitless peptide, the molecule your favorite biohacker swears, turns you
- 0:05into Bradley Cooper from the Limitless, just without the faw armor or the sex appeal.
- 0:09Alright, let's talk Dihexa. Originally developed by researchers at Washington State University,
- 0:13Dihexa is a small, orally active peptide that has gained a cult following in the biohacking
- 0:18community as the ultimate cognitive enhancer. Is this peptide really a genius maker or just
- 0:22another over-hyped compound destined for the supplement graveyard?
- 0:26Here's the science. Dihexa was specifically engineered to enhance cognitive function by
- 0:30targeting something called hepatocyte growth factors signaling in the brain.
- 0:33HGF is a protein that supports neuron growth, synaptic connectivity, and even promotes the
- 0:38creation of new neural pathways. Dihexa essentially acts as a powerful activator, promoting neurogenesis
- 0:44and neuroplasticity, which is a fancy way of saying it helps your brain build and strengthen
- 0:48connections. Now in animal studies, yes, mostly in rodents, Dihexa has shown some pretty impressive
- 0:53cognitive improvements. We're talking significant boosts in memory, learning, and problem-solving
- 0:57abilities and rats. These animal trials even suggest potential in treating neurodegenerative
- 1:01diseases like Alzheimer's, Parkinson's, and dementia. Pretty cool, right? Now if only they
- 1:05could fix me after years of energy drink abuse. But let's pump the brakes a little bit. Here's
- 1:09what you actually need to know. Human clinical data on Dihexa, virtually non-existent. Yes,
- 1:14animal studies are promising, but rodents aren't humans, and your biohacker buddy claiming
- 1:17photographic memory from Dihexa probably has some placebo effects going on. That being said,
- 1:22Dihexa does look genuinely intriguing from a biochemical standpoint. Its mechanism of action,
- 1:26enhancing HHF signaling and promoting neural growth could legitimately boost memory and cognition,
- 1:31potentially making it useful in therapeutic settings in the future. But as of now, it's
- 1:35purely experimental, not FDA-approved, and not even close to having robust human trials. Also,
- 1:40sourcing Dihexa means navigating the same sketchy gray market vendors online, so purity and quality
- 1:44are anyone's guess. Basically, you're rolling the dice with your neurons, which sounds like my
- 1:48average Friday night in college. What can I say? They'll let anyone to med school these days.
- 1:52I graduated with honors. Bottom line is Dihexo, the real-life limitless
- 1:56natrophic, probably not, or at least not yet. It has fascinating potential, impressive rodent data,
- 2:01and a genuinely unique biochemical mechanism. But right now, it's far more hype than human-tested
- 2:05reality. Proceed with extreme caution, keep your neurons safe, and maybe wait for actual clinical
- 2:10trials before betting your brain power on it. That's Dihexa. Limitless in theory, questionable
- 2:15in practice. Proceed accordingly.
Dihexa and cognition: what the rat studies actually show
Quick answer
Dihexa is a synthetic peptidomimetic developed at Washington State University that potentiates HGF/c-Met signaling, a pathway involved in neuronal survival and synaptic formation. All cognitive benefit data comes from rodent models, most prominently a 2013 study showing enhanced spatial memory in rats, with no published human pharmacokinetic, safety, or efficacy trials to date. Its investigational status means there is no established dosing, no regulatory-approved indication, and no clinical framework for evaluating risk in human populations.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 8 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Dihexa and cognition: what the rat studies actually show, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Emerging pharmacotherapies for obesity: A systematic review
Broad context for new and established obesity-drug categories.
PubMed
Glucagon-like receptor agonists and next-generation incretin-based medications
Current review for incretin-based obesity medications and cardiometabolic effects.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Dihexa and cognition: what the rat studies actually show is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.
Helpful context before the funnel
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "Dihexa and cognition: what the rat studies actually show" from Dr. Alex Tatem. We read the clip as a Peptide social video fact-checks claim about Peptide social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: Dihexa is a synthetic peptidomimetic developed at Washington State University that potentiates HGF/c-Met signaling, a pathway involved in neuronal survival and synaptic formation.
The reason this review is not generic is the source wording and the canonical claim label "peptides meet dihexa the so called limitless peptide your favorite bi." In this clip, the useful excerpt is: "Dihexa, aka the limitless peptide, the molecule your favorite biohacker swears, turns you into Bradley Cooper from the Limitless, just without the faw armor or the sex appeal." That wording changes the review because it points to Peptide social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.
The source trail for this page is checked against Emerging pharmacotherapies for obesity: A systematic review (2025), Glucagon-like receptor agonists and next-generation incretin-based medications (2026), and Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference (2025), plus the creator's own wording. Peptide social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
Dihexa is a synthetic peptidomimetic developed at Washington State University that potentiates HGF/c-Met signaling, a pathway involved in neuronal survival and synaptic formation.
FormBlends verdict
Peptide social video fact-checks evidence, safety, and patient-fit context
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- Dihexa is a synthetic peptidomimetic developed at Washington State University that potentiates HGF/c-Met signaling, a pathway involved in neuronal survival and synaptic formation. All cognitive benefit data comes from rodent models, most prominently a 2013 study showing enhanced spatial memory in rats, with no published human pharmacokinetic, safety, or efficacy trials to date. Its investigational status means there is no established dosing, no regulatory-approved indication, and no clinical framework for evaluating risk in human populations.
- Zero published human clinical trials for Dihexa exist as of 2024, making any claim about its cognitive effects in people speculative by definition.
- The 2013 McCoy et al. study in rodents showed potency several orders of magnitude greater than BDNF in a memory model, which is the actual basis for most Dihexa enthusiasm online.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- Zero published human clinical trials for Dihexa exist as of 2024, making any claim about its cognitive effects in people speculative by definition.
- The 2013 McCoy et al. study in rodents showed potency several orders of magnitude greater than BDNF in a memory model, which is the actual basis for most Dihexa enthusiasm online.
- HGF/c-Met signaling, the pathway Dihexa targets, is also studied in oncology for its role in tumor growth (Christensen et al., 2005, Cancer Research), a safety consideration no biohacking source adequately flags.
- Hay et al. (2014, Nature Biotechnology) found that over 90 percent of drug candidates that show efficacy in animals fail in human trials, which is the baseline odds for any rodent-only compound.
- Placebo effects in unblinded self-experiments with cognitive compounds are substantial and well-documented (Colagiuri et al., 2012), making user testimonials on forums and TikTok unreliable as evidence.
- Gray-market peptide vendors frequently provide inaccurate certificates of analysis, meaning consumers have no reliable way to verify what they are actually taking or at what concentration.
- The creator's overall framing, promising in theory, unproven in practice, is one of the more accurate takes on Dihexa circulating on social media, even if it missed the cancer-pathway risk entirely.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What did @dr..alex.tatem actually say?
The creator described Dihexa as a small, orally active peptide developed at Washington State University that works by activating hepatocyte growth factor (HGF) signaling in the brain. They credited it with promoting neurogenesis and neuroplasticity in animal models, suggested potential relevance to neurodegenerative conditions, and then pulled the brakes: "human clinical data on Dihexa, virtually non-existent." They also flagged gray-market sourcing as a real risk and landed on "limitless in theory, questionable in practice."
That's a reasonably honest summary for a 60-second TikTok. The creator doesn't promise cognitive transformation or tell viewers to buy anything. The skepticism is genuine, not performative. That matters more than it might seem on a platform where peptide hype runs rampant.
Does the science back this up?
Yes, mostly. The foundational animal research is real, and the HGF mechanism is legitimate neuroscience. But the creator leans on rodent data harder than the evidence probably warrants without flagging just how far that data is from clinical application.
Dihexa (also called PNB-0408) was developed by Joseph Harding and colleagues at Washington State University. A widely cited 2013 study published in the Journal of Pharmacology and Experimental Therapeutics (McCoy et al., 2013) showed that Dihexa outperformed the cognitive effects of BDNF in a scopolamine-induced amnesia rat model by several orders of magnitude in potency. That's the rodent data everyone cites. It's real. It's also from 2013, and there has been no published randomized controlled trial in humans since. The mechanism, enhancing HGF/c-Met signaling to promote synaptogenesis, is biologically plausible. HGF is expressed in the brain and does support neuronal survival and synaptic remodeling (Korhonen et al., 2000, Experimental Neurology). The leap from plausible mechanism plus rodent results to human cognitive enhancement, however, is a leap the evidence has not made.
What did they get wrong (or right)?
They got the core facts right. They got a few details sloppy. And they missed one risk worth naming explicitly.
On the factual side: the WSU origin, the HGF mechanism, the rodent-only evidence base, the lack of FDA approval, and the gray-market sourcing problem are all accurately described. Credit where it's due.
The sloppiness: at one point the creator says "HHF signaling" instead of HGF. Minor verbal slip, but in a health video watched by 200K people, precision matters. More substantively, the creator briefly mentions Alzheimer's, Parkinson's, and dementia as potential targets. That framing edges toward implying Dihexa could treat these diseases. It cannot, based on current evidence, and calling it a potential therapeutic "in the future" without a harder disclaimer risks giving viewers false hope about a completely unproven compound.
The missed risk: HGF signaling is not consequence-free. HGF and its receptor c-Met are implicated in tumor growth and metastasis in several cancer types (Christensen et al., 2005, Cancer Research). Chronically upregulating this pathway in healthy humans is not a proven-safe move. The creator should have said that plainly.
What should you actually know?
Dihexa is genuinely interesting as a research compound. It is not a supplement, not a therapy, and not something with a known human safety profile.
- No published human clinical trials exist for Dihexa as of 2024. The pipeline from rodent cognition studies to approved human treatments takes an average of 12-plus years and fails more than 90 percent of the time (Hay et al., 2014, Nature Biotechnology).
- Sourcing Dihexa through gray-market vendors means you have no verified information on purity, concentration, or contamination. Third-party certificate of analysis documents from these vendors are frequently unreliable.
- The HGF/c-Met pathway that Dihexa targets is the same pathway studied in oncology for its role in cancer progression. This is not a reason to panic, but it is a reason why "wait for clinical trials" is not just regulatory caution. It is basic prudence.
- Placebo effects in unblinded self-experimentation with nootropics are well-documented and substantial (Colagiuri et al., 2012, Experimental and Clinical Psychopharmacology). The biohacker testimonials the creator references are not evidence.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Dr. Alex Tatem · TikTok creator
203.7K views on this video
Meet Dihexa — the so-called “Limitless Peptide” your favorite biohacker swears will unlock Einstein mode🧠 Developed at Washington State University, it boosts HGF signaling, promoting neurogenesis and synaptic growth — at least in rats. 🐀 💡 Sounds genius-level, but here’s the truth: No human trials. No FDA approval. No verified dosing. Just gray-market hype and risky sourcing. If you value your neurons, maybe wait for science to catch up before playing Bradley Cooper IRL. 👨⚕️ Education only.
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about zero published human clinical trials for dihexa exist as of?
Zero published human clinical trials for Dihexa exist as of 2024, making any claim about its cognitive effects in people speculative by definition.
What does the video say about the 2013 mccoy et al. study in rodents showed potency?
The 2013 McCoy et al. study in rodents showed potency several orders of magnitude greater than BDNF in a memory model, which is the actual basis for most Dihexa enthusiasm online.
What does the video say about hgf/c-met signaling, the pathway dihexa targets,?
HGF/c-Met signaling, the pathway Dihexa targets, is also studied in oncology for its role in tumor growth (Christensen et al., 2005, Cancer Research), a safety consideration no biohacking source adequately flags.
What does the video say about hay et al. (2014, nature biotechnology) found?
Hay et al. (2014, Nature Biotechnology) found that over 90 percent of drug candidates that show efficacy in animals fail in human trials, which is the baseline odds for any rodent-only compound.
What does the video say about placebo effects in unblinded self-experiments with cognitive compounds?
Placebo effects in unblinded self-experiments with cognitive compounds are substantial and well-documented (Colagiuri et al., 2012), making user testimonials on forums and TikTok unreliable as evidence.
What does the video say about gray-market peptide vendors frequently provide inaccurate certificates of analysis, meaning?
Gray-market peptide vendors frequently provide inaccurate certificates of analysis, meaning consumers have no reliable way to verify what they are actually taking or at what concentration.
Sources & references
- [1]McCoy et al., 2013)
- [2]Korhonen et al., 2000
- [3]Christensen et al., 2005
- [4]Hay et al., 2014
- [5]Colagiuri et al., 2012
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Dr. Alex Tatem, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.